Business
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area,
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) (\"Protagonist\" or \"the Company\") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery, pre-clinical and translational research and development leadership to maximize the impact of the Protagonist platform in areas where peptides have the ability to be best-in-class therapeutics.\"We are very pleased to welcome Dr. Yeilding to Protagonist as our full-time Chief Scientific Advisor,\" said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. \"With extensive experience in research, development, and commercialization of novel therapeutics in the I&I space, Newman will be a great addition to the Protagonist R&D team as we expand our pipeline over the short- and long-term with drug candidates with blockbuster potential, including the oral peptide IL-17 antagonist program.\"\"I am delighted to be joining the Protagonist team,\" said Dr. Yeilding. \"Peptide therapeutics have the ability to be significantly more effective than small molecule or antibody-based drugs for many serious and life-threatening diseases. I look forward to working with the Protagonist team to maximize the impact of the company's peptide technology platform and continue bringing meaningful therapeutic innovations out of the lab and into clinical practice and patient care.\"Dr. Yeilding joins Protagonist following his 17-year career at Janssen, where he held a number of senior roles including Head of Immunology Development and R&D, Vice President of Immunology Dermatology, GI Development Senior Director, Vice President Immunology, and STELARA and Early Development Compound Development Team Leader. During his time at Janssen, he provided scientific and management leadership of immunology development initiatives in clinical departments in...